|Application ||WB, E|
|Calculated MW||70144 Da|
|Antigen Region||105-133 aa|
|Other Names||RecQ-mediated genome instability protein 1, BLM-associated protein of 75 kDa, BLAP75, FAAP75, RMI1, C9orf76|
|Target/Specificity||This RMI1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 105-133 amino acids from the N-terminal region of human RMI1.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||RMI1 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Essential component of the RMI complex, a complex that plays an important role in the processing of homologous recombination intermediates to limit DNA crossover formation in cells. Promotes TOP3A binding to double Holliday junctions (DHJ) and hence stimulates TOP3A-mediated dissolution. Required for BLM phosphorylation during mitosis. Within the BLM complex, required for BLM and TOP3A stability.|
|Cellular Location||Nucleus. Note=Forms foci in response to DNA damage|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
RMI1 is a component of protein complexes that limit DNA crossover formation via the dissolution of double Holliday junctions (Raynard et al., 2006 [PubMed 16595695]).[supplied by OMIM].
Yang, J., et al. J. Biol. Chem. 285(28):21426-21436(2010)
Frank, B., et al. Carcinogenesis 31(3):442-445(2010)
Barber, M.J., et al. PLoS ONE 5 (3), E9763 (2010) :
Luedeke, M., et al. Cancer Epidemiol. Biomarkers Prev. 18(11):3030-3035(2009)
Broberg, K., et al. BMC Cancer 9, 140 (2009) :
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.